You have 9 free searches left this month | to do more

Dacarbazine

Dacarbazine is a drug used to treat Melanoma, Lymphoma, Hodgkin Lymphoma, and other conditions. Dacarbazine is being actively studied in 39 studies and prior, has been studied in 60.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbMemorial Sloan Kettering Cancer CenterChristine Mauz-Korholz
National Cancer Institute (NCI)University of Michigan Comprehensive Cancer CenterProf. Dr. Peter Borchmann
AstraZenecaBeth Israel Deaconess Medical CenterGALIA AVRAHAMI
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • Classical Hodgkin Lymphoma
  • Dacarbazine
  • +4 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
2022-03-10
Mar 10, 2022
N
Completed
  • Malignant Melanoma
  • Recurrent Melanoma
  • Dacarbazine
  • +2 more
  • (no location specified)
2020-10-18
Oct 18, 2020
P
Recruiting
  • Leiomyosarcoma
  • Jacksonville, Florida
  • +4 more
2022-03-14
Mar 14, 2022
S
Recruiting
  • LMS - Leiomyosarcoma
  • Uterine Leiomyosarcoma
  • Stanford, California
    Stanford University
2022-02-11
Feb 11, 2022
P
Not yet recruiting
  • Leiomyosarcoma
  • (no location specified)
2022-02-25
Feb 25, 2022
I
Recruiting
  • Solitary Fibrous Tumors
  • Prato, Firenze, Italy
  • +5 more
2021-10-29
Oct 29, 2021
C
Completed
  • Stage IV Melanoma
  • recombinant interferon alfa-2b
  • +4 more
  • Cleveland, Ohio
    Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Ce
2020-07-22
Jul 22, 2020
S
Recruiting
  • Hodgkin Lymphoma, Adult
  • Moscow, Russian Federation
    The Federal Budget-Funded Institution National Medical Surgical
2020-11-20
Nov 20, 2020
U
Active, not recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    University Hospital of Cologne
2021-04-06
Apr 6, 2021
N
Terminated
  • Melanoma
  • St. Petersburg, Russian Federation
  • +2 more
2019-11-22
Nov 22, 2019
P
Recruiting
  • Soft Tissue Sarcoma
  • Dacarbazine
  • onfekafusp alfa
  • Münster, Germany
    Münster University Hospital
2022-03-16
Mar 16, 2022
U
Not yet recruiting
  • Hodgkin Lymphoma
  • Involved site radiotherapy
  • +6 more
  • (no location specified)
2021-09-27
Sep 27, 2021
B
Completed
  • Melanoma
  • BMS-936558 (Nivolumab)
  • +3 more
  • Capital Federal, Buenos Aires, Argentina
  • +74 more
2021-08-02
Aug 2, 2021
U
Recruiting
  • Classical Hodgkin Lymphoma
  • Cologne, Germany
    University Hospital of Cologne
2021-06-11
Jun 11, 2021
T
Completed
  • Metastatic Uveal Melanoma
  • Wirral, United Kingdom
    Clatterbridge Centre for Oncology NHS Foundation Trust
2019-10-27
Oct 27, 2019
M
Terminated
  • Melanoma
  • PTK787/ZK 222584
  • Dacarbazine
  • Essen, Germany
  • +3 more
2021-09-28
Sep 28, 2021
M
Completed
  • Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +2 more
  • Boston, Massachusetts
  • +1 more
2020-08-10
Aug 10, 2020
T
Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
2022-04-06
Apr 6, 2022
H
Recruiting
  • Classical Hodgkin Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2020-12-29
Dec 29, 2020
A
Terminated
  • Metastatic Melanoma
  • Charlotte, North Carolina
  • +8 more
2020-11-03
Nov 3, 2020
N
Completed
  • HIV Infections
  • Hodgkin's Disease
  • Vinblastine sulfate
  • +4 more
  • Birmingham, Alabama
  • +7 more
2021-10-26
Oct 26, 2021
M
Completed
  • Malignant Melanoma
  • Pembrolizumab
  • +4 more
  • (no location specified)
2020-04-29
Apr 29, 2020